innoscripta Under Investigation: Warburg Pulls 225-Euro Target as Shares Hit New Low

German tax-criminal probe into innoscripta's research grant advisory triggers stock freefall; Warburg Research suspends rating and EUR 225 price target.

Raids on the premises of innoscripta SE and affiliated group companies have turned a high-margin advisory story into a legal gamble, and the market has wasted little time repricing the risk. Investigators searched the business premises as part of a tax-criminal probe, and the stock has been in freefall ever since.

The suspicion at the heart of the case is that the company aided and abetted unjustified tax benefits in connection with client applications for research grants. The searches rest on orders issued by the Schwäbisch Gmünd local court dated 3 August and 15 September. innoscripta has said that, based on preliminary findings, the matter may trace back to possible misconduct by individual employees on certain client mandates. The company has pledged full cooperation with investigators while conceding that the financial and operational consequences cannot currently be quantified. It also pointed out that clients themselves are responsible for the accuracy and completeness of the information they submit to the authorities.

A Business Built on Trust, Now Under Scrutiny

The structural vulnerability here is not hard to spot. innoscripta helps companies claim state innovation funding in a legally secure manner — a service that lives entirely on trust and integrity. When a provider whose entire model rests on regulatory precision and tax compliance draws the attention of prosecutors, more than day-to-day operations is at stake. The question of which mid-sized or large corporate client will still want to use an adviser whose prepared applications trigger search warrants is not a theoretical one. The risk of a wave of mandate cancellations and a collapse in new business is, for many observers, an acute threat rather than a distant scenario.

The share price tells its own story. The stock lost more than half its value on Thursday, then fell a further 12% to EUR 33.00 on Friday. Earlier in Friday's session the paper marked a new 52-week low of EUR 33.05, before trading at EUR 36.50 — still a daily loss of 3.0%.

Warburg Steps Back

Warburg Research reacted swiftly, suspending both its rating and its previous DCF price target of EUR 225. The reasoning lays bare just how far the valuation had to fall. Such a target presupposes an intact operating business model. At innoscripta, 56% of calculated enterprise value was attributable to the terminal value, underpinned by an assumed sustainable EBIT margin of 55%. Those are precisely the assumptions now under fire.

The analysts see tangible risks: stricter application reviews by authorities, looming client losses, civil liability claims, clawbacks of revenue by regulators, and potentially severe corporate penalties. High-profit margins and long-term growth projections of this kind can only be justified as long as the business model remains intact. If market access erodes through reputational damage, or if regulatory tightening forces a fundamental realignment, those calculations implode.

Clarity Before Hope

A reliable revaluation is only conceivable once there is clarity about the affected mandates and employees. Equally, the course of the proceedings, the stability of the order pipeline, future approval rates, and possible provisions all need to be assessed. Until management can demonstrate beyond doubt that this was the misconduct of individuals and that internal control systems are effective, the chance-risk profile argues against any engagement. A months-long limbo looms — one that could swallow substantial legal costs and paralyse new business alike. The case makes plain that regulatory and criminal risks in the subsidy environment leave no room for grey zones. For investors, the situation remains defined by grave uncertainty.